Form SCHEDULE 13G Outlook Therapeutics, Filed by: Empery Asset Management, LP

Tue, 13 Oct 2026 12:47:00 -0400

si-local-file:///var/storage/secattach/20261013/27180184.html

Outlook Therapeutics names Greg DiPasquale as CCO ahead of U.S. launch

Fri, 09 Oct 2026 08:30:28 -0400

Outlook Therapeutics, Inc. (Nasdaq: OTLK) has appointed Greg DiPasquale as Chief Commercial Officer, the company said in a statement. DiPasquale, who joined Outlook in December 2025 as Head of Commercial, will oversee market access, commercial operations, marketing, sales, and reimbursement functions.

The appointment comes as the company prepares to make Lytenava (bevacizumab-vikg) available to patients in the United States before the end of 2026. Lytenava holds FDA approval as the only ophthalmic formulation of bevacizumab indicated for the treatment of wet age-related macular degeneration.

DiPasquale brings more than 30 years of commercial experience, including nearly two decades in eye care. His prior

Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer

Fri, 09 Oct 2026 08:30:00 -0400

Veteran retina commercial leader, who has helped launch BEOVU®, EYLEA® and EYLEA® HD, to lead U.S. commercialization of LYTENAVA™ (bevacizumab-vikg)

ISELIN, N.J., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced Greg DiPasquale as Chief Commercial Officer. Mr. DiPasquale, who joined Outlook in December 2025 as Head of Commercial for LYTENAVA™, will lead all commercial functions as the Company prepares to make LYTENAVA, the first and only FDA-approved ophthalmic formulation of bevacizumab for the

Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer

Fri, 09 Oct 2026 08:30:00 -0400

Veteran retina commercial leader, who has helped launch BEOVU®, EYLEA® and EYLEA® HD, to lead U.S. commercialization of LYTENAVA™ (bevacizumab-vikg)

Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion

Tue, 06 Oct 2026 09:20:00 -0400

Segment features Kevin Lundquist discussing his decision to join Outlook Therapeutics and the Company’s path forward following the FDA approval of LYTENAVA™

Access the segment here

ISELIN, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that it participated in a Virtual Investor "What This Means" segment featuring Kevin Lundquist, the Company’s recently appointed Chief Financial Officer

Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion

Tue, 06 Oct 2026 09:20:00 -0400

Segment features Kevin Lundquist discussing his decision to join Outlook Therapeutics and the Company’s path forward following the FDA approval of LYTENAVA™

Access the segment here

Outlook Therapeutics files for permanent J-code for Lytenava with CMS

Thu, 01 Oct 2026 09:02:17 -0400

Outlook Therapeutics, Inc. (Nasdaq: OTLK) has submitted an application to the Centers for Medicare & Medicaid Services (CMS) requesting a permanent, product-specific Healthcare Common Procedure Coding System (HCPCS) Level II J-code for its drug Lytenava (bevacizumab-vikg), according to a press release.

Lytenava is the only FDA-approved ophthalmic formulation of bevacizumab and is indicated for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). The company states it remains on track for a U.S. commercial launch before the end of 2026.

HCPCS Level II J-codes are standardized codes used by government and commercial payers to facilitate billing and reimbursement for physician-administered treatments.

Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)

Thu, 01 Oct 2026 09:01:00 -0400

Application represents an important step in supporting reimbursement

Company remains on track for U.S. commercial launch of LYTENAVA before year-end 2026

ISELIN, N.J., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that it has submitted an application to the Centers for Medicare & Medicaid Services (CMS) requesting a permanent, product-specific Healthcare Common Procedure Coding System (HCPCS) Level II J-code for LYTENAVA.

The

Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)

Thu, 01 Oct 2026 09:01:00 -0400

Application represents an important step in supporting reimbursement

Company remains on track for U.S. commercial launch of LYTENAVA before year-end 2026

The

Form 8-K Outlook Therapeutics, For: Sep 25

Wed, 30 Sep 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260930/27129034.html

Form 8-K Outlook Therapeutics, For: Sep 16

Fri, 18 Sep 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260918/27080893.html

Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand

Fri, 11 Sep 2026 07:00:00 -0400

Fireside chat featuring Bob Jahr, Chief Executive Officer, and H.C. Wainwright Managing Director & Senior Biotechnology Equity Research Analyst

Access the video webcast here

ISELIN, N.J., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that its pre-recorded fireside chat from the H.C. Wainwright 28th Annual Global Investment Conference (the “Conference”) is now available for on-demand viewing here.

Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand

Fri, 11 Sep 2026 07:00:00 -0400

Fireside chat featuring Bob Jahr, Chief Executive Officer, and H.C. Wainwright Managing Director & Senior Biotechnology Equity Research Analyst

Access the video webcast here

Outlook Therapeutics CEO discusses Lytenava FDA approval and U.S. launch

Thu, 10 Sep 2026 09:10:17 -0400

Outlook Therapeutics, Inc. (Nasdaq: OTLK) announced that Chief Executive Officer Bob Jahr participated in a Virtual Investor CEO Connect segment to discuss the FDA approval of LYTENAVA (bevacizumab-vikg) and the company's plans for a U.S. commercial launch before the end of 2026.

LYTENAVA is described by the company as the only FDA-approved ophthalmic formulation of bevacizumab, indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD). The drug has also received Marketing Authorization from the European Commission and the UK's Medicines and Healthcare products Regulatory Agency for the same indication.

During the segment, Jahr discussed the company's goal of achieving more

Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment

Thu, 10 Sep 2026 09:10:00 -0400

Access the segment here

ISELIN, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that Bob Jahr, Chief Executive Officer, recently participated in a Virtual Investor CEO Connect segment discussing the significance of the FDA approval of LYTENAVA and the Company’s plans for its U.S. commercial launch.

During the segment, Mr. Jahr discusses the potential of LYTENAVA to address the

Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment

Thu, 10 Sep 2026 09:10:00 -0400

Access the segment here

During the segment, Mr. Jahr discusses the potential of LYTENAVA to address the

Form 8-K Outlook Therapeutics, For: Aug 23

Thu, 27 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260827/26990014.html

Form 8-K Outlook Therapeutics, For: Aug 23

Thu, 27 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260827/26990014.html

Outlook Therapeutics names Kevin Lundquist as CFO ahead of U.S. launch

Thu, 27 Aug 2026 16:05:34 -0400

Outlook Therapeutics, Inc. (Nasdaq: OTLK) has appointed Kevin Lundquist as Chief Financial Officer, effective September 1, 2026, as the biopharmaceutical company prepares for the U.S. commercial launch of its FDA-approved drug LYTENAVA (bevacizumab-vikg).

Lundquist brings more than 20 years of corporate finance and capital markets experience across the pharmaceutical, biotechnology, medical technology, and manufacturing industries. He most recently served as CFO of CapsoVision, Inc., a commercial-stage medical technology company, where he led the company through its 2025 IPO process and oversaw finance, operations, SEC reporting, and capital raises.

Prior to CapsoVision, Lundquist was CFO of Abzena Biologics, a private equity-backed contract development

Outlook Therapeutics names Kevin Lundquist as CFO ahead of U.S. launch

Thu, 27 Aug 2026 16:05:34 -0400

Prior to CapsoVision, Lundquist was CFO of Abzena Biologics, a private equity-backed contract development

Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™

Thu, 27 Aug 2026 16:05:00 -0400

Seasoned finance executive brings more than 20 years of leadership experience across global commercial organizations, including the pharmaceutical and medical technology industries

Deep expertise spans commercial operations, capital markets, public company finance, and building scalable financial and operational infrastructure

Appointment strengthens financial and operational infrastructure as Company prepares for U.S. commercial launch following FDA approval of LYTENAVA™

Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™

Thu, 27 Aug 2026 16:05:00 -0400

Appointment strengthens financial and operational infrastructure as Company prepares for U.S. commercial launch following FDA approval of LYTENAVA™

Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference

Thu, 27 Aug 2026 09:01:00 -0400

Video webcast now available here

ISELIN, N.J., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that Bob Jahr, Chief Executive Officer, recently participated in the Virtual Investor “Why Now” on-demand conference.

During the segment, Mr. Jahr highlighted why he believes Outlook Therapeutics is entering a transformative period following the FDA’s approval of LYTENAVA™ on July 24, 2026, making it the

Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference

Thu, 27 Aug 2026 09:01:00 -0400

Video webcast now available here

During the segment, Mr. Jahr highlighted why he believes Outlook Therapeutics is entering a transformative period following the FDA’s approval of LYTENAVA™ on July 24, 2026, making it the

Form SCHEDULE 13G Outlook Therapeutics, Filed by: CVI Investments, Inc.

Wed, 19 Aug 2026 13:47:00 -0400

si-local-file:///var/storage/secattach/20260819/26949380.html

StreetInsider.com News Articles

Form SCHEDULE 13G Outlook Therapeutics, Filed by: Empery Asset Management, LP

Outlook Therapeutics names Greg DiPasquale as CCO ahead of U.S. launch

Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer

Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer

Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion

Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion

Outlook Therapeutics files for permanent J-code for Lytenava with CMS

Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)

Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)

Form 8-K Outlook Therapeutics, For: Sep 25

Form 8-K Outlook Therapeutics, For: Sep 16

Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand

Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand

Outlook Therapeutics CEO discusses Lytenava FDA approval and U.S. launch

Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment

Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment

Form 8-K Outlook Therapeutics, For: Aug 23

Form 8-K Outlook Therapeutics, For: Aug 23

Outlook Therapeutics names Kevin Lundquist as CFO ahead of U.S. launch

Outlook Therapeutics names Kevin Lundquist as CFO ahead of U.S. launch

Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™

Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™

Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference

Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference

Form SCHEDULE 13G Outlook Therapeutics, Filed by: CVI Investments, Inc.